Comparative Pharmacology
Head-to-head clinical analysis: OXAPROZIN versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXAPROZIN versus TOLECTIN DS.
OXAPROZIN vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which results in anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
600-1200 mg orally once daily; maximum 1800 mg/day.
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 50–60 hours in healthy adults; clinical context: once-daily dosing achieves steady-state in 7–10 days.
Clinical Note
moderateOxaprozin + Gatifloxacin
"Oxaprozin may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateOxaprozin + Rosoxacin
"Oxaprozin may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateOxaprozin + Levofloxacin
"Oxaprozin may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateOxaprozin + Trovafloxacin
"Oxaprozin may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Primarily hepatic metabolism (glucuronidation and hydroxylation) with renal excretion of metabolites; less than 1% excreted unchanged in urine; fecal elimination accounts for ~20%.
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category D/X
Category C
NSAID
NSAID